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Abstract In the brain, Glud1-encoded glutamate dehy-
drogenase plays a major role in the recycling of the neu-
rotransmitter glutamate. We recently reported a new model
of brain-specific Glud1 null mice (Cns-Glud1-/-) lacking
glutamate dehydrogenase in the central nervous system.
Cns-Glud1-/- mice exhibit reduced astrocytic glutamate
breakdown and redirection of glutamate pathways without
altering synaptic transmission. Cns-Glud1-/- mice were
generated using LoxP and Nestin-Cre technology. Nestin-
Cre mice are widely used to investigate gene deletion in the
central nervous system. However, the Nes-Cre transgene
itself was reported to induce a phenotype related to body
weight gain. Here, we review the potential side-effects of
Nes-Cre and analysed Cns-Glud1-/- body weight gain.
Overall, Nestin-Cre mice may exhibit transient and mod-
erate growth retardation during the few weeks immediately
following weaning. Pending appropriate controls and
homogenization of the genetic background, Nestin-Cre
technology is a valuable tool enabling disruption of genes
of interest in the central nervous system.
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Glucose is the major source of energy delivered to the central
nervous system (CNS) by peripheral organs. However,
within the brain, oxidative catabolism of the neurotrans-
mitter glutamate might significantly contribute to ATP pro-
duction and maintenance of energy homeostasis. Upon
glutamate transmission, intersynaptic glutamate clearance is
achieved mostly by astrocytes [1]. Active astrocytic inter-
nalization of glutamate also ensures detoxification of the
extracellular space. However, altered glutamate handling is
associated with various neurodegenerative diseases; such as
Parkinson’s disease, epilepsy, schizophrenia, and Alzhei-
mer’s disease [2]. Following its uptake by astrocytes gluta-
mate may be amidated to glutamine and then recycled back
to glutamate once transferred to neurons (Fig. 1a). Alterna-
tively, astrocytic glutamate may be deaminated to a-keto-
glutarate within mitochondria. This pathway is catalysed
either by transaminases or by glutamate dehydrogenase
(GDH) before oxidative catabolism in the TCA cycle,
thereby promoting ATP generation [3]. In the CNS, GDH is
predominantly expressed in astrocytes and to lower levels in
neurons [4, 5]. GDH catalyses either the anabolic amination
of a-ketoglutarate to glutamate or the catabolic oxidation of
glutamate [3]. The enzyme forms homohexamers in mito-
chondria and is encoded by Glud1 in all vertebrates [6].
Additionally, a second isoform is found in humans [7], being
expressed mostly in astrocytes and testicular supporting cells
[8].
We recently reported a new model of brain-specific
Glud1 null mice (Cns-Glud1-/-) lacking GDH in the CNS
[9]. In astrocytes lacking GDH, oxidative catabolism of
glutamate to CO2 is reduced, indicating lower astrocytic
glutamate breakdown. However, brain-targeted NMR
measurements have shown that Cns-Glud1-/- glutamate
levels are maintained to control values, while glutamine
concentrations are increased in Cns-Glud1-/- brains [9].
This modified pattern of glutamate/glutamine ratio does not
induce over-excitability or hypo-excitability. These data
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suggest preservation of glutamate homeostasis in GDH-
null brains, at the expense of an increase in glutamine
formation. Redirection of glutamate pathways in Cns-
Glud1-/- brains is apparently favoured by up-regulation of
astrocyte-type glutamate and glutamine transporters and of
glutamine synthetase (Fig. 1b and [9]). The Cns-Glud1-/-
mouse model represents a unique tool to explore the
importance of GDH as a key enzyme connecting glucose
and glutamate metabolism within the CNS. Furthermore,
given the dys-regulation of glutamate in neurodegenerative
diseases, GDH appears as a potent target for management
of related neurological disorders.
We generated the Cns-Glud1-/- brain-specific GDH
knockout mice by crossing Glud1 floxed (Glud1lox/lox) mice
[10] with animals expressing the Cre recombinase under the
control of Nestin cis-regulatory (Nes-Cre) sequence [11].
Heterozygous Cns-Glud1?/- were then crossed with Glu-
d1lox/lox mice to obtain homozygous Cns-Glud1-/-, while
Cre was kept heterozygous [9]. In this specific study [9],
animals were maintained on a mixed genetic background
(C57BL/6 J 9 129/Sv) to avoid inbred strain-specific phe-
notypes. Accordingly, floxed Glud1lox/lox littermates of
Cns-Glud1-/- knockouts were used as control animals to
optimize standardization of the genetic background between
the two groups [9]. In other words, only Cns-Glud1-/-
knockout mice carried the Nes-Cre transgene. No gender
differences were noticed.
The Cre transgenic lines represent invaluable tools to
explore the role of a given protein in a specific tissue
(conditional knockout), that can additionally be time-spe-
cific (inducible Cre systems). Nevertheless, one should
consider appropriate controls according to potential Cre-
mediated effects. Some studies have reported side effects
or phenotypes associated with Cre activity or transgene
insertion [12–14]. For instance, the cause of haematologi-
cal abnormalities after the systemic activation of CreERT2
described by Higashi et al. [15] was proposed to be the
consequence of Cre-mediated genomic rearrangements.
Such rearrangement within the mouse genome might hap-
pen at pseudo-loxP sites, which have been shown to serve
as substrates for Cre recombinase [15–17]. Some of the
unexpected phenotypes associated with the presence of the
Cre transgene might be due to the disruption of the genome
loci where the transgene was integrated.
Another potential confounding effect of Cre technology is
the misplaced recombination of the floxed target-gene. This
is illustrated by some mouse models used to study insulin-
secreting cells. In order to target Cre-mediated recombina-
tion of floxed genes specifically in pancreatic beta-cells,
Rip-Cre mice have been generated. These animals express the
Cre recombinase under the control of the rat insulin (Ins2)
promoter (Rip-Cre). However, infidelity of Rip-Cre transgene
in the hypothalamus has been noticed in one transgenic line
(Tg(Ins2-cre)25Mgn) [18], although not particularly in another
one (Tg(Ins2-cre)1Herr) [19], potentially altering gene
expression in nutrient-sensing neurons [20]. Such undesired
hypothalamic effect might render the transgenic animals more
likely to develop glucose intolerance under specific genetic
backgrounds. Indeed, it was shown that perturbations in glu-
cose homeostasis observed in a Tg(Ins2-cre)25Mgn transgenic
line [18] can be accounted for by differences in genetic
background [21]. Therefore, misplaced recombination com-
bined with C57BL/6 J background might influence metabolic
homeostasis and potentially contribute to a phenotype not
fully specific for the beta-cell.
Some studies may have attributed roles to a target-gene,
which were in fact partly or fully due to Cre toxicity.
Limitation of Cre technology should not hide other possi-
ble pitfalls, potentially more disturbing. Indeed, Cre-med-
iated effects do not rule out alternative major confounding
factors, primarily the genetic background, as discussed
Fig. 1 Abrogation of GDH in brain affects glutamate handling.
a Simplified representation of glutamate fates in astrocytes and
neurons (aKG, a-ketoglutarate; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; EAAT 1/2, excitatory amino acid trans-
porters 1/2; GDH, glutamate dehydrogenase; Gln, glutamine; GLS,
glutaminase; Glu, glutamate; GS, glutamine synthetase; SNAT 3/7,
sodium-coupled amino acid transporters 3/7; vGLUT1, vesicular
glutamate transporter 1). b Protein levels analysed by immunoblotting
[9] of enzymes/transporters related to glutamate pathway in brains
from CNS-specific Glud1 knockout (Cns-Glud1-/-) and Glud1lox/lox
floxed control (C-floxed) mice. Actin (for GDH) and ezerin (for GS,
EAAT2 and SNAT3) served as loading control. Values are
mean ± SE, n = 2–5, * p \ 0.05 and ** p \ 0.01 using the Student’s
t test
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above. Whenever possible, the genetic background should
be homogenized between the studied groups [22], similarly
to human studies based on twins [23].
Nestin-Cre mice are widely used to investigate gene
deletion and cell function in the CNS. However, the Nes-Cre
transgene itself was reported to induce a phenotype related
to body weight gain. Indeed, it was observed that Nestin-Cre
mice have smaller body weights [24], an effect not observed
by others [25]. These apparently conflicting results have not
been particularly highlighted to the scientific community, as
they appeared as Supplementary Materials [24] and
Addendum [25] to their respective papers. Maintained on a
pure C57BL/6J background, Nestin-Cre mice purchased
from the Jackson Laboratory (Origin, R. Klein, EMBL)
display mild hypopituitarism [26]. Discrepancies between
laboratories regarding body growth suggest that Nes-Cre
transgene may render animals more susceptible to factors
such as the genetic background or subtle environment
specificities. This might have physiological consequences,
in particular when Nes-Cre transgene is associated with the
deletion of genes implicated in metabolic control. The
widespread use of Nestin-Cre mice has led to an increasing
awareness of potential strain-dependent differences in body
weight of these mice.
Given these strain differences, we further evaluated the
Cns-Glud1-/- mice by comparing these conditional
knockout animals with both Nestin-Cre controls carrying
the Nes-Cre transgene (C-Cre) and Glud1-floxed controls
lacking Nes-Cre but having loxP sites in the Glud1 gene
(C-floxed). Immunobloting analyses showed comparable
GDH expression in C-Cre and C-floxed brains as well as in
non-excitable peripheral tissues known to express GDH
(Fig. 2a). Brain GDH enzymatic activity was not signifi-
cantly different between the two transgenic control groups,
i.e. C-Cre and C-floxed mice (Fig. 2b). On the contrary, in
brain homogenates of Cns-Glud1-/- mice we observed
abrogation of GDH activity, both in the oxidative deami-
nation and in the reductive amination directions. Wild type
control (C-wt) mice exhibited brain GDH activity
Fig. 2 Expression and activity of GDH in Cns-Glud1-/- mice.
a Brain-specific GDH deletion in Cns-Glud1-/- mice was assessed by
immunoblotting. GDH expression in brains was compared with non-
excitable tissues collected from Glud1lox/lox floxed control (C-floxed),
Nes-Cre control (C-Cre) and CNS-specific Glud1 knockout (Cns-
Glud1-/-) mice. Actin served as loading control. Immunoblots are
representative of 3 independent preparations. b Brain GDH enzymatic
activity of C-floxed, C-Cre, Cns-Glud1-/-, and wild type control (C-
wt) mice measured in both oxidative and reductive directions [10],
using glutamate (Glu) and a-ketoglutarate (a-KG) as substrates,
respectively. Values are mean ± SE, n = 5–7, * p \ 0.05 and **
p \ 0.01 using one-way ANOVA
Fig. 3 Effects of Nes-Cre and Cns-Glud1-/- on body weight. a Body
weights from Glud1lox/lox floxed control (C-floxed), Nes-Cre control
(C-Cre), CNS-specific Glud1 knockout (Cns-Glud1-/-), and wild
type control (C-wt) mice recorded over 16 weeks of life after birth.
b Increases in body weight for periods of 6 weeks measured over 2–8,
4–10 and 6–12 weeks of age. Values are mean ± SE; n = 7–27; *
p \ 0.05, ** p \ 0.01 C-Cre versus C-wt; #p \ 0.05, ##p \ 0.01
C-Cre versus C-floxed, using one-way ANOVA
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comparable to the transgenic controls C-Cre and C-floxed
(Fig. 2b). Regarding body growth, we observed lower body
weights associated with Nes-Cre transgene at the age of
7–8 weeks (Fig. 3a) contributed by reduced weight gain
during the weeks immediately following weaning (Fig. 3b).
The effect was transient and C-Cre animals could catch up
body weight in comparison with the other transgenic groups
by the age of 10 weeks when body growth stabilized.
However, compared to wild type animals having more a
C57BL/6J black 6 background, body weights remained
slightly lower. Therefore, at the age of 10 weeks onwards, no
significant differences in body weights were observed
between transgenic mice maintained on a similar mixed
genetic background, carrying or not Nes-Cre transgene; i.e.
either C-Cre or Cns-Glud1-/- versus Nes-Cre-free C-floxed
mice. According to these results, we favoured analyses of
Cns-Glud1-/- mice at the age of 10 weeks onwards [9].
In conclusion, use of Nestin-Cre mice requires special
attention regarding interpretation of body weight gain, in
particular during the few weeks immediately following
weaning. Pending appropriate controls and homogenization
of the genetic background, Nestin-Cre technology is a
valuable tool enabling disruption of genes of interest in the
CNS. For instance, Cns-Glud1-/- mice lacking GDH in the
CNS uncovered the fine tuning and compartmentalization
of glutamate-glutamine handling in the brain.
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